Research & Development

20 Aug 2019
- Drug Discovery
- Research & Development
Angel-funded Siamab completes £166m exit with large commercial-stage biopharma

By PBR Staff Writer

Siamab Therapeutics, a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202m (£166m) with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialise antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.
20 Aug 2019
Drug Discovery
Research & Development
Mexico-based Sanfer gets £413m investment from CDPQ

By PBR Staff Writer

Caisse de dépôt et placement du Québec (CDPQ), a Canadian long-term institutional investor, has agreed to make a minority investment of $500m (£413.8m) in Mexican pharmaceutical company Sanfer.
19 Aug 2019
Drug Discovery
Research & Development
Xynomic Research Institute successfully designs series of potent RET kinase inhibitors

By PBR Staff Writer

Xynomic Pharmaceuticals Holdings, a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (XRI) has successfully designed a series of potent RET kinase inhibitors by computer-assisted drug design.
16 Aug 2019
Drug Discovery
Research & Development
GeneCentric Therapeutics acquires Select ImmunoGenomics

By PBR Staff Writer

GeneCentric Therapeutics announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs.
14 Aug 2019
Drug Discovery
Research & Development
Landos Biopharma completes £49.7m series B financing

By PBR Staff Writer

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, announced the successful completion of its $60m (£49.7m) Series B financing round.
13 Aug 2019
Drug Discovery
Research & Development
Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares

By PBR Staff Writer

Eidos Therapeutics has received a non-binding proposal dated August 8, 2019 (the Proposal) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (BridgeBio), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio.
13 Aug 2019
Drug Discovery
Research & Development
Boehringer Ingelheim, MD Anderson to jointly advance new cancer therapies

By PBR Staff Writer

Boehringer Ingelheim has forged a multi-year partnership with The University of Texas MD Anderson Cancer Center to carry out joint research towards rapid advancement of new therapies for various forms of cancers.
13 Aug 2019
Drug Discovery
Research & Development
Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m

By PBR Staff Writer

Jazz Pharmaceuticals has acquired US-based clinical-stage biotechnology company Cavion for a total potential consideration of $312.5m (£258.9m).
12 Aug 2019
Drug Discovery
Research & Development
Ascletis opens Clinical Development Shanghai Center

By PBR Staff Writer

Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of its Clinical Development Shanghai Center, signalling the further expansion of R&D capability, especially in Oncology and Non-alcoholic steatohepatitis (NASH).
09 Aug 2019
Drug Discovery
Research & Development
Bayer to buy remaining stake in BlueRock Therapeutics

By PBR Staff Writer

Bayer has agreed to acquire the remaining 50.2% interest in US-based biotechnology company BlueRock Therapeutics for around $240m (£197m) in cash.

Drug Discovery

Research & Development

Agilent and Monash University Malaysia to set up biodiscovery hub

FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Research & Development

Angel-funded Siamab completes £166m exit with large commercial-stage biopharma

Mexico-based Sanfer gets £413m investment from CDPQ

Xynomic Research Institute successfully designs series of potent RET kinase inhibitors

GeneCentric Therapeutics acquires Select ImmunoGenomics

Landos Biopharma completes £49.7m series B financing

Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares

Boehringer Ingelheim, MD Anderson to jointly advance new cancer therapies

Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m

Ascletis opens Clinical Development Shanghai Center

Bayer to buy remaining stake in BlueRock Therapeutics

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found